Mitochondrial peptides attract attention because they connect energy regulation, aging biology, and metabolic resilience. MOTS-c is often discussed in that frame.
The practical risk is narrative inflation. Mechanistic appeal can be real while clinical certainty remains limited.
For the product, this type of story works best as a signal to monitor: relevant enough to explain, not strong enough to convert into guidance.